Other interesting sessions for CML patient advocates

1. How to Get Published in a Peer-Reviewed Journal

PhD Trainee
Program: Special-Interest Sessions
Saturday, December 7, 2019: 11:15 AM-12:15 PM
W307, Level 3 (Orange County Convention Center)
Chair: Bob Löwenberg, MD, PhD, Editor-in-Chief, Blood, Erasmus University Medical Center.

The ability to communicate one's work effectively by publication in high-impact journals is a benchmark for success in academic medicine. Even high-quality work may not be accepted if not presented in a well-crafted manuscript. This talk will provide insight into the elements of a high-quality manuscript worthy of publication in Blood and tips on avoiding common errors that might result rejection.

2. FDA-Sponsored Patient Advocate Meeting

Program: Special-Interest Sessions
Monday, December 9, 2019: 12:30 PM-1:30 PM
W206A (ED Office) (Orange County Convention Center)

Annually, reviewers from the U.S. Food and Drug Administration (FDA) and leadership from the Oncology Center of Excellence and the Office of Hematology and Oncology host a session intended to foster dialogue between reviewers of benign and malignant hematology drug products and patients affected by the drug approval process. The session will be interactive and allow time for discussion between the FDA reviewers and the patients.

3. Diving Into Rare Childhood Leukemias

Program: Spotlight Sessions
Chair: Oussama Abla, MD, Hospital for Sick Children Division of Hematology
Monday, December 9, 2019: 2:45 PM-4:15 PM
W307, Level 3 (Orange County Convention Center)

Since first described over thirty years ago, acute leukemia defying conventional lineage assignment as ALL or AML have posed a therapeutic conundrum. With only limited insight available into the underlying biology for "bi-phenotypic" or "mixed phenotype acute leukemia (MPAL)," treatment included therapy intended for AML, ALL, or a combination of both with or without stem cell transplantation. Only recently, an intensive focus on the genomic landscape for MPAL has combined with a growing number of international cohort studies to result in a rapid evolution in our understanding of this rare disease.

Childhood Chronic myeloid leukemia (CML) is a rare disease. Recent data indicates biological differences between adults and children. Evidence-based guidelines have been established for adult CML, but it is challenging to develop similar recommendations in pediatrics because of the rarity of the disease. Recent approval of second-generation tyrosine kinase inhibitors (TKI) in addition to imatinib has provided more treatment options for pediatric patients, but limited data on efficacy and safety often makes management difficult. Further, host factors are different in actively growing children and children develop distinct morbidities of TKI, such as delayed growth.

Dr. Etan Orgel will explore the emerging data for MPAL biology and clinical outcomes as they relate to therapy selection and future research directions. Dr. Nobuko Hijiya will discuss the recent advances in the biology of childhood CML, challenges to the management of children, and the feasibility of a pediatric TKI "Stopping" study.